4D Molecular Therapeutics, Inc. (FDMT) Operating income 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) annual operating income history from SEC filings — each fiscal year as reported.
-$159.5MFY2025 · since FY2019: -$50.8M → -$159.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$159.5M | +15.1% |
| FY2024 | -$187.8M | -66.4% |
| FY2023 | -$112.9M | -2.6% |
| FY2022 | -$110.0M | -54.3% |
| FY2021 | -$71.3M | -25.9% |
| FY2020 | -$56.7M | -11.6% |
| FY2019 | -$50.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More FDMT financial trends
FDMT RevenueFDMT Net incomeFDMT Net marginFDMT Gross profitFDMT Gross marginFDMT Operating marginFDMT Operating cash flowFDMT Free cash flowFDMT Capital expendituresFDMT Return on equityFDMT Stock buybacksFDMT Dividends paidFDMT Total assetsFDMT Total liabilitiesFDMT Shareholders’ equityFDMT overview →